Novartis acquisition validates CIRM’s impact on cystinosis treatment

Dr. Stephanie Cherqui The future looks brighter for cystinosis patients and their families.   As one of 7,000 rare diseases, cystinosis causes an abnormal build-up of the amino acid cystine that can lead to organ failure and premature death. With little to no treatment options, children and young adults primarily affected by the condition often have … Continue reading Novartis acquisition validates CIRM’s impact on cystinosis treatment

CIRM invests $10 million to build California Cell and Gene Therapy Manufacturing Network

A laboratory at UCLA's current good manufacturing practices facility | Photo credit: Elena Zhukova The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded $10 million to five facilities as part of the first phase to build a California Cell and Gene Therapy Manufacturing Network. The awards include: Application … Continue reading CIRM invests $10 million to build California Cell and Gene Therapy Manufacturing Network